Call Us: +91-9915015108
Pantoprazole is a proton pump inhibitor that decreases the amount of acid produced in the stomach. Pantoprazole is used to treaterosive esophagitis (damage to the esophagus from stomach acid), and other conditions involving excess stomach acid such as Zollinger-Ellison syndrome.
Domperidone stimulates GI activity by acting as a competitive antagonist at dopamine D2 receptor.
Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production by covalently binding to the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. The binding to the (H+, K+)-ATPase results in a duration of antisecretory effect that persists longer than 24 hours for all doses tested (20 mg to 120 mg).
Pantoprazole is PPI suppresses the final step in gastric acid production. Pantoprazole is unstable in acid & is administered orally in the form of an enteric coated tablet. Pantoprazole is completely & rapidly absorbed after oral administration. The absolute bioavailability from the tablet was found to be about 77%. Pantoprazole is extensively metabolized in the liver through cytochrome P 450 (CYP) system. Domperidone acts as a gastrointestinal emptying adjunct & peristaltic stimulant. The gastro kinetic properties of Domperidone are related to its peripheral dopamine receptor blocking properties, In fasting subjects, Domperidone is rapidly absorbed after oral administration. Domperidone is 91-93% bound to plasma proteins.
Pantoprazole is contraindicated in hepatic impairment hypersensitivity.
Pantoprazole may reduce the absorption of active substances whose bioavailability is dependent on the gastric phase. Pantoprazole is metabolized in the liver via the cytochrome P450 enzyme system. An interaction of Pantoprazole are metabolized by the same enzyme system cannot be excluded.
